Parametric Portfolio Associates LLC grew its holdings in shares of Castle Biosciences (NASDAQ:CSTL) by 364.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,635 shares of the company’s stock after purchasing an additional 40,529 shares during the period. Parametric Portfolio Associates LLC owned approximately 0.30% of Castle Biosciences worth $1,539,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its position in shares of Castle Biosciences by 165.8% during the 1st quarter. Ameritas Investment Partners Inc. now owns 824 shares of the company’s stock valued at $25,000 after purchasing an additional 514 shares in the last quarter. Citigroup Inc. boosted its holdings in shares of Castle Biosciences by 1,174.8% in the fourth quarter. Citigroup Inc. now owns 2,078 shares of the company’s stock worth $71,000 after buying an additional 1,915 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of Castle Biosciences in the fourth quarter worth about $74,000. SG Americas Securities LLC acquired a new position in shares of Castle Biosciences in the first quarter worth about $112,000. Finally, Bank of America Corp DE boosted its holdings in shares of Castle Biosciences by 148.4% in the fourth quarter. Bank of America Corp DE now owns 4,359 shares of the company’s stock worth $150,000 after buying an additional 2,604 shares during the period. Institutional investors own 42.74% of the company’s stock.
In other news, Director Joseph C. Cook III sold 900 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $37.03, for a total value of $33,327.00. Following the sale, the director now owns 208,053 shares in the company, valued at $7,704,202.59. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bonnie H. Anderson sold 3,000 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $30.25, for a total transaction of $90,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 584,087 shares of company stock worth $22,056,304. 39.70% of the stock is currently owned by corporate insiders.
NASDAQ:CSTL opened at $37.69 on Wednesday. The company’s 50 day moving average is $37.90 and its 200-day moving average is $31.99. The firm has a market cap of $604.25 million and a price-to-earnings ratio of -43.83. The company has a quick ratio of 7.56, a current ratio of 7.64 and a debt-to-equity ratio of 0.19. Castle Biosciences has a 12 month low of $15.26 and a 12 month high of $44.53.
Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.18. The business had revenue of $17.42 million for the quarter, compared to the consensus estimate of $14.40 million. Castle Biosciences had a net margin of 11.90% and a return on equity of 3.88%. Research analysts predict that Castle Biosciences will post -0.5 EPS for the current fiscal year.
CSTL has been the subject of several recent analyst reports. SVB Leerink raised their target price on shares of Castle Biosciences from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Zacks Investment Research lowered shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 15th. Canaccord Genuity increased their price target on shares of Castle Biosciences from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, May 21st. Robert W. Baird reduced their price target on shares of Castle Biosciences from $38.00 to $35.00 and set an “outperform” rating for the company in a research report on Friday, March 27th. Finally, BTIG Research raised their price objective on shares of Castle Biosciences from $32.00 to $41.00 in a research report on Wednesday, March 11th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Castle Biosciences presently has a consensus rating of “Buy” and an average price target of $39.00.
About Castle Biosciences
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Recommended Story: Yield Curve
Want to see what other hedge funds are holding CSTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Castle Biosciences (NASDAQ:CSTL).
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.